base-metals-investing FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
base-metals-investing Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
base-metals-investing Independent Study Presented at American Society of Hematology Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
base-metals-investing Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
base-metals-investing Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
base-metals-investing Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
base-metals-investing Ryoncil® Receives J-Code From Medicare & Medicaid Services Facilitating Reimbursement and Broader Patient Access
base-metals-investing Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
CORRECTION - Domestic Metals Engages ICP Securities Inc. for Automated Market Making Services and provides further details on the engagement of Michael Pound
